Women with estrogen receptor (ER)-positive breast cancer are treated with hormonal agents targeting the ER, and can remain free of disease for many years. However, resistance to treatment eventually develops, and these women will thus suffer a recurrence of their cancer. In our current grant period, we explored our proposal that the key to the successful treatment of these women is to focus on identifying novel mechanisms of resistance, using metastatic tumors resistant to hormone therapy in which tumor evolution and clonal selection for resistance have already occurred. Using this innovative approach, we have already discovered several new individual resistance mechanisms, including reduced levels of two key negative regulators of resistance - Rho guanine dissociation inhibitor alpha (Rho GDIa) and the growth factor receptor scaffolding protein SLC9A3R1, both of which enhance activation of ERa via its phosphorylation. We will focus on these two resistance mechanisms, and determine their effect on cells with wild-type ERa as well as two specific ERa mutations (lysine 303 and tyrosine 537) that we were the first to discover in breast tumors, and which significantly affect hormone response. We will exploit these resistance mechanisms to exert more precise control over resistant tumor growth, combining hormonal and targeted therapy along with knowledge of the activation status of the key ERa growth pathway. Therefore, we now propose to validate specific resistance mechanisms associated with losses of Rho GDIa or SLC9A3R1 and their effects on ERa, to target these specific mechanisms, and to translate these findings to pinpoint predictive clinical biomarkers and potential treatment targets.
Our Aims are: (1) To target SLC9A3R1 and Rho GDIa resistance mechanisms to restore hormone sensitivity and response to targeted therapies;(2) To determine how SLC9A3R1 and Rho GDIa.resistance pathways pact on mutant ERa function;and (3) To validate selected candidates from these two pathways for their ability to predict resistance to targeted hormone and biologic therapies, using our extensive retrospective clinical breast tumor resources. This work should lead to extended effective suppression of recurrence for the large numbers of women with ER-positive breast cancer who now daily fear reappearance of their disease in spite of continued endocrine treatment.

Public Health Relevance

Over 135,000 women per year are diagnosed with ER-positive breast cancer and hormonal agents are their best targeted option, however, many women will progress in spite of this therapy. We propose to identify novel mechanisms of hormone resistance, and utilize these as novel therapeutic biologic targets and as predictive biomarkers for patients receiving treatment with hormonal agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA072038-16A1
Application #
8759014
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Sathyamoorthy, Neeraja
Project Start
1996-09-01
Project End
2019-08-31
Budget Start
2014-09-22
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$319,275
Indirect Cost
$116,775
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Gelsomino, Luca; Gu, Guowei; Rechoum, Yassine et al. (2016) ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat 157:253-65
Gu, Guowei; Fuqua, Suzanne A W (2016) ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action. Clin Cancer Res 22:1034-6
Ciupek, Andrew; Rechoum, Yassine; Gu, Guowei et al. (2015) Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Breast Cancer Res Treat 154:225-37
Gu, Guowei; Gelsomino, Luca; Covington, Kyle R et al. (2015) Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat 150:535-45
Covington, Kyle R; Fuqua, Suzanne A W (2014) Role of MTA2 in human cancer. Cancer Metastasis Rev 33:921-8
Fuqua, Suzanne A W; Gu, Guowei; Rechoum, Yassine (2014) Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144:11-9
Rechoum, Yassine; Rovito, Daniela; Iacopetta, Domenico et al. (2014) AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 147:473-85
Razandi, M; Pedram, A; Jordan, V C et al. (2013) Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 32:3274-85
De Amicis, Francesca; Russo, Alessandra; Avena, Paola et al. (2013) In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res 57:840-53
Covington, Kyle R; Brusco, Lauren; Barone, Ines et al. (2013) Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat :

Showing the most recent 10 out of 45 publications